Using RNA sequencing databases of cancer patients, the researchers found that STAT3 and STAT5 work together to control the quantity of dendritic cells. Through transcriptional signaling, each protein ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

The work further revealed how an MDM2-targeted therapy could turn the anticancer protein back on, thereby extending survival in model systems. The findings were published today in Cancer Cell. In a ...

NF-κB can suppress p53 levels by upregulating the expression of MDM2, a target gene of NF-kB. Since MAPKs are regulated by reversible phosphorylation on threonine and tyrosine residues, deactivation ...

KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors KT-253 is a highly potent and selective heterobifunctional degrader of the MDM2 ...